IL288950B2 - History of pyridine-3-yl - Google Patents
History of pyridine-3-ylInfo
- Publication number
- IL288950B2 IL288950B2 IL288950A IL28895021A IL288950B2 IL 288950 B2 IL288950 B2 IL 288950B2 IL 288950 A IL288950 A IL 288950A IL 28895021 A IL28895021 A IL 28895021A IL 288950 B2 IL288950 B2 IL 288950B2
- Authority
- IL
- Israel
- Prior art keywords
- model
- technical unit
- attack
- test
- computer system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Debugging And Monitoring (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019065963 | 2019-06-18 | ||
| PCT/EP2020/066767 WO2020254408A1 (en) | 2019-06-18 | 2020-06-17 | Pyridin-3-yl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL288950A IL288950A (en) | 2022-02-01 |
| IL288950B1 IL288950B1 (en) | 2024-11-01 |
| IL288950B2 true IL288950B2 (en) | 2025-03-01 |
Family
ID=71105482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288950A IL288950B2 (en) | 2019-06-18 | 2020-06-17 | History of pyridine-3-yl |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12479820B2 (enExample) |
| EP (1) | EP3986884B1 (enExample) |
| JP (1) | JP7494222B2 (enExample) |
| KR (1) | KR102786045B1 (enExample) |
| CN (1) | CN114026082B (enExample) |
| AR (1) | AR119162A1 (enExample) |
| AU (1) | AU2020298014B2 (enExample) |
| BR (1) | BR112021025236A2 (enExample) |
| CA (1) | CA3143618A1 (enExample) |
| CL (1) | CL2021003348A1 (enExample) |
| IL (1) | IL288950B2 (enExample) |
| MA (1) | MA56504A (enExample) |
| MX (1) | MX2021015727A (enExample) |
| PH (1) | PH12021553178A1 (enExample) |
| SG (1) | SG11202111162PA (enExample) |
| TW (1) | TWI845708B (enExample) |
| UA (1) | UA130692C2 (enExample) |
| WO (1) | WO2020254408A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE061559T2 (hu) | 2018-06-07 | 2023-07-28 | Idorsia Pharmaceuticals Ltd | Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk |
| WO2021110805A1 (en) * | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| WO2025169931A1 (ja) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | カルボキサミド化合物 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130088C (enExample) | 1960-03-14 | |||
| WO1994006802A1 (fr) * | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AU7961300A (en) | 1999-10-29 | 2001-05-14 | Yamanouchi Pharmaceutical Co., Ltd. | Kainic acid neurocytotoxicity inhibitors |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| WO2005037269A1 (ja) | 2003-10-21 | 2005-04-28 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ピペリジン誘導体 |
| CA2544981A1 (en) | 2003-11-12 | 2005-05-26 | Merck & Co., Inc. | 4-phenyl piperidine sulfonyl glycine transporter inhibitors |
| EP1687296A1 (en) | 2003-11-18 | 2006-08-09 | Warner-Lambert Company LLC | Antibacterial aminoquinazolidinedione derivatives |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| TWI377198B (en) | 2005-08-24 | 2012-11-21 | Eisai R&D Man Co Ltd | Novel pyridine derivatives and pyrimidine derivatives (3) |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| WO2008115281A2 (en) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| AU2008311971A1 (en) | 2007-10-18 | 2009-04-23 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| EP2297153B1 (en) | 2008-04-21 | 2015-05-27 | Lexicon Pharmaceuticals, Inc. | Limk2 inhibitors, compositions comprising them, and methods of their use |
| AU2009243756B2 (en) | 2008-05-05 | 2013-06-27 | Sanofi-Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| BRPI0918971A2 (pt) | 2008-08-26 | 2015-12-01 | Boehringer Ingelheim Int | tienopirimidinas para composições farmacêuticas |
| JP5708936B2 (ja) | 2009-09-25 | 2015-04-30 | アステラス製薬株式会社 | 置換アミド化合物 |
| ES2682303T3 (es) | 2010-08-05 | 2018-09-19 | Zoetis Services Llc | Derivados de isoxazolina como agentes antiparasitarios |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| CN107721940A (zh) | 2010-12-07 | 2018-02-23 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| PT2683723T (pt) | 2011-03-10 | 2016-08-05 | Zoetis Services Llc | Derivados espirocíclicos de isoxazolina como agentes antiparasitários |
| JP2015506349A (ja) | 2011-12-21 | 2015-03-02 | アルデリックス， インコーポレイテッド | 非全身性ｔｇｒ５アゴニスト |
| WO2014079805A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| TW201444820A (zh) * | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| JP2017500287A (ja) | 2013-11-06 | 2017-01-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体 |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| HUE061559T2 (hu) | 2018-06-07 | 2023-07-28 | Idorsia Pharmaceuticals Ltd | Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
-
2020
- 2020-06-16 AR ARP200101686A patent/AR119162A1/es unknown
- 2020-06-17 EP EP20733601.7A patent/EP3986884B1/en active Active
- 2020-06-17 AU AU2020298014A patent/AU2020298014B2/en active Active
- 2020-06-17 KR KR1020227001133A patent/KR102786045B1/ko active Active
- 2020-06-17 SG SG11202111162PA patent/SG11202111162PA/en unknown
- 2020-06-17 CN CN202080044333.8A patent/CN114026082B/zh active Active
- 2020-06-17 UA UAA202107611A patent/UA130692C2/uk unknown
- 2020-06-17 PH PH1/2021/553178A patent/PH12021553178A1/en unknown
- 2020-06-17 MX MX2021015727A patent/MX2021015727A/es unknown
- 2020-06-17 IL IL288950A patent/IL288950B2/en unknown
- 2020-06-17 WO PCT/EP2020/066767 patent/WO2020254408A1/en not_active Ceased
- 2020-06-17 US US17/620,520 patent/US12479820B2/en active Active
- 2020-06-17 TW TW109120315A patent/TWI845708B/zh active
- 2020-06-17 MA MA056504A patent/MA56504A/fr unknown
- 2020-06-17 BR BR112021025236A patent/BR112021025236A2/pt unknown
- 2020-06-17 CA CA3143618A patent/CA3143618A1/en active Pending
- 2020-06-17 JP JP2021574814A patent/JP7494222B2/ja active Active
-
2021
- 2021-12-15 CL CL2021003348A patent/CL2021003348A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7494222B2 (ja) | 2024-06-03 |
| WO2020254408A1 (en) | 2020-12-24 |
| EP3986884A1 (en) | 2022-04-27 |
| IL288950A (en) | 2022-02-01 |
| CN114026082A (zh) | 2022-02-08 |
| AR119162A1 (es) | 2021-12-01 |
| AU2020298014B2 (en) | 2026-02-05 |
| CA3143618A1 (en) | 2020-12-24 |
| US20220251068A1 (en) | 2022-08-11 |
| TWI845708B (zh) | 2024-06-21 |
| MA56504A (fr) | 2022-04-27 |
| CL2021003348A1 (es) | 2022-09-23 |
| KR102786045B1 (ko) | 2025-03-24 |
| JP2022537177A (ja) | 2022-08-24 |
| EP3986884B1 (en) | 2026-07-08 |
| US12479820B2 (en) | 2025-11-25 |
| BR112021025236A2 (pt) | 2022-02-01 |
| AU2020298014A1 (en) | 2022-02-10 |
| IL288950B1 (en) | 2024-11-01 |
| CN114026082B (zh) | 2024-06-07 |
| UA130692C2 (uk) | 2026-04-22 |
| PH12021553178A1 (en) | 2022-11-07 |
| MX2021015727A (es) | 2022-01-24 |
| KR20220020921A (ko) | 2022-02-21 |
| SG11202111162PA (en) | 2021-11-29 |
| TW202115011A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12386969B2 (en) | Method for checking the security of a technical unit | |
| US11366748B1 (en) | Fuzzy testing a software system | |
| US8413237B2 (en) | Methods of simulating vulnerability | |
| Moukahal et al. | Vulnerability-oriented fuzz testing for connected autonomous vehicle systems | |
| Bach et al. | Data-driven development, a complementing approach for automotive systems engineering | |
| US20130031532A1 (en) | Method, computer, and device for validating execution of tasks in adaptable computer systems | |
| CN120811778A (zh) | 一种基于虚拟攻防推演的电力网络漏洞分析系统及方法 | |
| CN120705875A (zh) | 基于ai与区块链的智能合约自动优化与风险预警方法及系统 | |
| Marksteiner et al. | A model-driven methodology for automotive cybersecurity test case generation | |
| CN117290848A (zh) | 基于ai分析的软件组件稳定性测试方法及大数据服务系统 | |
| CN121727861B (zh) | 基于协议解析差异的waf防御能力测试方法及装置 | |
| US20240428128A1 (en) | Computing system for implementing system model using big data machine learning | |
| US20220382865A1 (en) | Persistent security configuration monitoring | |
| KR20240126308A (ko) | 차량 내부 네트워크의 보안을 평가하기 위한 방법 | |
| Moradi et al. | Machine learning-assisted fault injection | |
| Marksteiner et al. | Approaches for automating cybersecurity testing of connected vehicles | |
| Loper | The modeling and simulation life cycle process | |
| EP4401016A1 (en) | Method for generating and training a system model, selecting a controller, system, computer-system | |
| US12468870B2 (en) | Method and system for carrying out a simulation | |
| Gilliam et al. | Addressing software security and mitigations in the life cycle | |
| Bouquet et al. | Model-based testing for functional and security test generation | |
| CN116057539A (zh) | 用于评估和认证基于ai的信息处理系统的鲁棒性的方法和装置 | |
| CN119094198B (zh) | 一种基于TTPs脚本的攻击链数据自动生成采集方法 | |
| Jabr et al. | Simulated penetration testing and attack automation using deep reinforcement learning | |
| CN115834187B (zh) | 车辆控制器漏洞管理方法、系统、电子设备、存储介质 |